Saved in:
Bibliographic Details
Main Authors: Raulf, Karoline, Koller, Timm O, Beckert, Bertrand, Lepak, Alexander, Morici, Martino, Mardirossian, Mario, Scocchi, Marco, Bange, Gert, Wilson, Daniel N
Format: Artículo científico
Language:en
Published: Nucleic acids research 2025
Subjects:
Online Access:https://pubmed.ncbi.nlm.nih.gov/40331629/
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • The structure of the Vibrio natriegens 70S ribosome in complex with the proline-rich antimicrobial peptide Bac5(1-17). Raulf, Karoline Koller, Timm O Beckert, Bertrand Lepak, Alexander Morici, Martino Mardirossian, Mario Scocchi, Marco Bange, Gert Wilson, Daniel N Vibrio Cryoelectron Microscopy Ribosomes Binding Sites Antimicrobial Peptides Models, Molecular Protein Biosynthesis Protein Binding Proline Peptides, Cyclic Proline-rich antimicrobial peptides (PrAMPs) are produced as part of the innate immune response of animals, insects, and plants. The well-characterized mammalian PrAMP bactenecin-5 (Bac5) has been shown to help fight bacterial infection by binding to the bacterial ribosome and inhibiting protein synthesis. In the absence of Bac5-ribosome structures, the binding mode of Bac5 and exact mechanism of action has remained unclear. Here, we present a cryo-electron microscopy structure of Bac5 in complex with the 70S ribosome from the Gram-negative marine bacterium Vibrio natriegens. The structure shows that, despite sequence similarity to Bac7 and other type I PrAMPs, Bac5 displays a completely distinct mode of interaction with the ribosomal exit tunnel. Bac5 overlaps with the binding site of both A- and P-site transfer RNAs bound at the peptidyltransferase center, suggesting that this type I PrAMP can interfere with late stages of translation initiation as well as early stages of elongation. Collectively, our study presents a ribosome structure from V. natriegens, a fast-growing bacterium that has interesting biotechnological and synthetic biology applications, as well as providing additional insights into the diverse binding modes that type I PrAMPs can utilize to inhibit protein synthesis.